IGFBP2 and obesity due to melanocortin 4 receptor deficiency: These observations suggest a potential dual effect for IGFBP-2 in breast cancer development: IGFBP-2 may reduce the risk of AH via protection against development of insulin resistance and by virtue of its inverse association with obesity, while concurrently increasing risk of AH via its proliferative effects on breast tissue.